Österrike - tyska - AGES (Agentur für Gesundheit und Ernährungssicherheit)

richter pharma ag - felines calicivirus (fcv); panleukopenievirus, felin; rhinotracheitisvirus, felin -

Tyskland - tyska - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

virbac tierarzneimittel gmbh (3091569) - felines rhinotracheitisvirus, stamm fhv f2, lebend; felines calicivirus, stamm f9, lebend; felines panleukopenievirus, stamm lr72, lebend; tollwutvirus, stamm vp 12, inaktiviert - lyophilisat und lösungsmittel zur herstellung einer injektionssuspension - felines rhinotracheitisvirus, stamm fhv f2, lebend (35300) 100000 gewebekultur-infektiöse-dosis 50%; felines calicivirus, stamm f9, lebend (35276) 39810,7171 gewebekultur-infektiöse-dosis 50%; felines panleukopenievirus, stamm lr72, lebend (35296) 5011,8723 gewebekultur-infektiöse-dosis 50%; tollwutvirus, stamm vp 12, inaktiviert (35202) 1 internationale einheit - katze

Tyskland - tyska - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

zoetis deutschland gmbh (4402304) - felines panleukopenievirus, stamm schneeleopard, lebend; felines rhinotracheitisvirus, fvrm-stamm, lebend; felines calicivirus, stamm f9, lebend; tollwut-virus, stamm flury lep, inaktiviert - lyophilisat und suspension zur herstellung einer injektionssuspension - felines panleukopenievirus, stamm schneeleopard, lebend (35294) 1000 gewebekultur-infektiöse-dosis 50%; felines rhinotracheitisvirus, fvrm-stamm, lebend (35299) 100000 gewebekultur-infektiöse-dosis 50%; felines calicivirus, stamm f9, lebend (35276) 316227,766 gewebekultur-infektiöse-dosis 50%; tollwut-virus, stamm flury lep, inaktiviert (31435) 3,25 internationale einheit - katze

Europeiska unionen - tyska - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europeiska unionen - tyska - EMA (European Medicines Agency)

zoetis belgium sa  - inactivated feline rhinotracheitis virus, inactivated feline calicivirus, inactivated feline chlamydophila felis, inactivated feline leukaemia virus, inactivated feline panleukopenia virus - immunologische - katzen - für die aktive immunisierung von gesunden katzen neun wochen oder älter gegen feline panleukopenie und feline leukämie-virus und gegen atemwegserkrankungen, hervorgerufen durch felines rhinotracheitis virus, felines calicivirus und chlamydophila felis.

Europeiska unionen - tyska - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europeiska unionen - tyska - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. anfänge der immunität wurden eine woche nach der grundimmunisierung für rhinotracheitis, calicivirus, chlamydophila felis und panleukopenie nachgewiesen. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Tyskland - tyska - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

lilly deutschland gmbh abteilung elanco animal health (4602055) - felines panleukopenievirus, stamm schneeleopard, lebend; felines rhinotracheitisvirus, fvrm-stamm, lebend; felines calicivirus, stamm f9, lebend - lyophilisat und lösungsmittel zur herstellung einer injektionssuspension - felines panleukopenievirus, stamm schneeleopard, lebend (35294) 1000 gewebekultur-infektiöse-dosis 50%; felines rhinotracheitisvirus, fvrm-stamm, lebend (35299) 100000 gewebekultur-infektiöse-dosis 50%; felines calicivirus, stamm f9, lebend (35276) 316227,766 gewebekultur-infektiöse-dosis 50% - katze

Österrike - tyska - AGES (Agentur für Gesundheit und Ernährungssicherheit)

merial s.a.s. - panleukopenievirus, felin -

Belgien - tyska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

zoetis belgium - feline rhinotracheitis-herpes-virus; feline chlamydophila (= chlamydia psittaci); panleucopenie feline parvovirus, live; calicivirus felines, live - injektionssuspension - feline rhinotracheitis-herpes-virus ; feline chlamydophila (= chlamydia psittaci) ; panleucopenie feline parvovirus, live ; calicivirus felines, live - feline panleucopenia virus / parvovirus + feline rhinotracheitis virus + feline calicivirus + feline infectious leukaemia virus + chlamydia - katze